Boehringer Withheld Evidence on Blood Thinner Dosing, BMJ Says

Boehringer Ingelheim GmbH didn’t tell regulators that adjusting the dose of blood thinner Pradaxa could make it safer, according to a BMJ probe into the drug that’s been linked to patient deaths.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.